Answer
Mothers should avoid breastfeeding throughout Tarceva (erlotinib) treatment and for at least 2 weeks after the final dose, because the potential for harm to the nursing infant is unknown.
Sources for this answer
- Tarceva 25 mg, 100 mg & 150 mg Film-coated TabletsRoche Products Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 11Document updated
Sources checked